Image Credit: depositphotos.com
In a significant advancement for bladder cancer diagnosis, a new at-home urine test has demonstrated a remarkable ability to detect 92 percent of bladder cancer cases in a recent trial involving nearly 1,000 patients across seven hospitals in England and Scotland. The test, named Galeas, was developed at the University of Birmingham with funding from Cancer Research UK and is now licensed to diagnostics company Nonacus. The findings have been published in the journal European Urology Oncology.
Galeas works by identifying genetic material shed by bladder cancer cells in urine, analyzing over 450 mutations across 23 genes associated with the disease. This innovative approach aims to streamline the diagnostic process by determining which patients require urgent cystoscopy, a procedure that is currently the standard for bladder cancer diagnosis but comes with discomfort and long waiting times.
In the UK, over 300,000 cystoscopies are performed annually, leading to significant backlogs in some regions. The introduction of a reliable urine test could alleviate this pressure, allowing for earlier intervention and saving clinical resources. When Galeas returns a negative result, there is a greater than 99 percent chance that the patient does not have bladder cancer, enhancing patient reassurance.
The next step for the researchers is to conduct a larger trial to further validate the test’s efficacy. If successful, this could lead to tens of thousands of patients avoiding cystoscopies each year. Bladder cancer primarily affects men over 60, with blood in the urine often serving as the main symptom. Early detection is crucial, as the prognosis depends on tumor size and whether the cancer has spread.
This breakthrough in bladder cancer testing underscores the ongoing efforts to find faster and less invasive diagnostic methods, potentially transforming the standard of care for patients.
Check out the original article here: Source link
